Suchergebnisse - "Glomerulosclerosis, Focal Segmental"

PubPharm (159)

41

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients : A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

enthalten in: ClinicalTrials.gov | 2022

42

Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis : An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects With Focal Segmental Glomerulosclerosis

enthalten in: ClinicalTrials.gov | 2021

43

Immunoglobulin M nephropathy : histopathological and clinical characteristics. Case series

enthalten in: Archivos argentinos de pediatria | 2021

von Meni Battaglia, L. | Balestracci, A. | Toledo, I. | +5

44

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria : Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE)

enthalten in: ClinicalTrials.gov | 2021

45

A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN) : A Study to Characterize the Genetic, Biomarker, and Clinical Profile of Patients With Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)

enthalten in: ClinicalTrials.gov | 2021

46

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) : A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change Disease)

enthalten in: ClinicalTrials.gov | 2021

47

Study to assess the safety and effectiveness of propagermanium as add-on therapy in FSGS patients who are already taking Irbesartan. : A Phase 2a, Double-blind, Randomised, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of Propagermanium in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) who are receiving Irbesartan

enthalten in: WHO International Clinical Trials Registry Platform | 2021

48

Study to assess the safety and effectiveness of propagermanium as add-on therapy in FSGS patients who are already taking Irbesartan. : A Phase 2a, Double-blind, Randomised, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of Propagermanium in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) who are receiving Irbesartan

enthalten in: WHO International Clinical Trials Registry Platform | 2021

49

Morphometric analysis of glomeruli, clinical features and outcome in obese and non-obese focal segmental glomerulosclerosis patients

in: Vojnosanitetski Pregled | 2021

von Jordanova Elena | Janković Radmila | Naumović Radomir | +4

50

Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease : Efficacy and Safety of Rituximab in Adult Patients With Refractory or Relapsed Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

enthalten in: ClinicalTrials.gov | 2020